CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
2.4939
0%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.1222
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 2.4939
Open 2.4739
1-Year Change 176.48%
Day's Range 2.4639 - 2.5239
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 11, 2024 2.4739 0.0600 2.49% 2.4139 2.5839 2.2839
Jun 10, 2024 2.3939 0.0000 0.00% 2.3939 2.4939 2.3439
Jun 7, 2024 2.4339 -0.0800 -3.18% 2.5139 2.5539 2.3739
Jun 6, 2024 2.6839 -0.0800 -2.89% 2.7639 2.7839 2.6739
Jun 5, 2024 2.8039 -0.0800 -2.77% 2.8839 2.9339 2.6839
Jun 4, 2024 2.8139 -0.2500 -8.16% 3.0639 3.1839 2.8139
Jun 3, 2024 3.0339 -0.1500 -4.71% 3.1839 3.4539 2.8639
May 31, 2024 3.0939 0.2700 9.56% 2.8239 3.8539 2.7239
May 30, 2024 2.3639 0.0300 1.29% 2.3339 2.4439 2.2839
May 29, 2024 2.2539 0.1700 8.16% 2.0839 2.3339 2.0539
May 28, 2024 2.1039 -0.0600 -2.77% 2.1639 2.2239 2.1039
May 24, 2024 2.1839 0.0100 0.46% 2.1739 2.2539 2.1639
May 23, 2024 2.1639 -0.1400 -6.08% 2.3039 2.3139 2.1439
May 22, 2024 2.3439 0.0700 3.08% 2.2739 2.3739 2.2739
May 21, 2024 2.3239 -0.1100 -4.52% 2.4339 2.4339 2.2939
May 20, 2024 2.4039 -0.0200 -0.83% 2.4239 2.4339 2.3639
May 17, 2024 2.4739 0.0600 2.49% 2.4139 2.5039 2.4139
May 16, 2024 2.4139 -0.0900 -3.59% 2.5039 2.5639 2.2939
May 15, 2024 2.4139 -0.0600 -2.43% 2.4739 2.4939 2.3839
May 14, 2024 2.5239 0.2200 9.55% 2.3039 2.6339 2.1639

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Genprex, Inc. Company profile

About Genprex Inc

Genprex, Inc. is a clinical-stage gene therapy company focused on developing treatments for cancer and diabetes. The Company's lead cancer drug candidate, REQORSA Immunogene therapy drug (also referred to as GPX-001), is being developed to treat non-small cell lung cancer (NSCLC). The active agent in REQORSA is a TUSC2 gene expressing plasmid that is encapsulated in a DOTAP cholesterol nanoparticle. TUSC2 is a tumor suppressor gene which has both tumor killing (via apoptosis) and immunomodulatory effects. The Company utilizes its ONCOPREX Nanoparticle Delivery System to deliver the TUSC2 gene expressing plasmid to cancer cells. Its diabetes gene therapy, also referred to as GPX-002, is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Genprex Inc revenues was not reported. Net loss increased 9% to $13.9M. Higher net loss reflects General and administrative increase of 13% to $8.8M (expense), Research and development increase of 3% to $5.1M (expense), Interest Income decrease of 76% to $4K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.39 to -$0.30.

Industry: Bio Therapeutic Drugs

1601 Trinity Street, Bldg. B
Suite 3.322
AUSTIN
TEXAS 78712
US

News

Bank of Japan Preview: Markets look for guidance from BOJ about timing of next hike

The Bank of Japan meets on Friday, 14th of June, 2024. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

11:05, 12 June 2024

FOMC preview: Still expecting three rate cuts in 2024?

The Federal Reserve is expected to keep its policy unchanged on Wednesday – data from Reuters shows a 99% chance of no change. Last week’s 25-basis-point rate cut from the ECB has done nothing to change market expectations, and why should it?

08:20, 11 June 2024

US Non-Farm Payrolls Preview: Forecasts point to a stable labour market

US labour market conditions are expected to have remained stable in May. The latest Non-Farm Payrolls data will be released on Friday, June 7th, 2024, and will provide a health check on the US jobs market.

10:09, 5 June 2024

AUD/USD analysis: Focus turns to GDP data after unexpected CPI rise

Higher-than-expected monthly CPI data watered down expectations for RBA interest rate cuts in 2024; the markets will now shift attention to quarterly GDP data on Wednesday, June 5.

15:57, 4 June 2024

ECB preview: A cut, but how many more?

After months of waiting, a rate cut from the ECB on Thursday looks like a done deal. Data from Reuters shows markets pricing in a 96% chance of a 25-basis point cut from the European Central Bank following Thursday’s policy meeting.

08:54, 4 June 2024

PCE Index Preview: Forecasts point to no change in headline or core inflation from a month earlier

The markets continue to look for signals of disinflation in the United States. The latest PCE Index data, the US Federal Reserve’s preferred inflation gauge, is released on May 31, 2024.

12:44, 29 May 2024

Gold and Silver recover from last week’s pullback but face resistance ahead of US PCE

Gold and Silver move higher after last week’s pullbacks but the precious metals are struggling with resistance ahead of the US PCE release.

15:46, 28 May 2024

People also watch

US100

19,588.60 Price
+1.980% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

ETH/USD

3,560.30 Price
+2.100% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

68,359.20 Price
+1.720% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

XRP/USD

0.50 Price
+2.110% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 620,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading